Claims
Agentic Learning"The model assigned only 57% probability of FDA approval before July 2027."Oct 01, 2026
MedPath Trial"The company plans to commercially launch lonvo-z in the first half of 2027, contingent on potential approval in the United States."Sep 09, 2026
The Motley FoolIntellia Therapeutics has submitted an application for regulatory approval for lonvo-z in the U.S., and the medicine could get the nod from regulators by March 2027.Sep 27, 2026
Intellia Therapeutics"The company is preparing for a potential U.S. launch of lonvo-z in the first half of 2027."Sep 29, 2026
Intellectia.AI"The firm notes the FDA accepted Intellia's BLA for lonvo-z in HAE and granted Priority Review, with a PDUFA date of March 10, 2027."Oct 01, 2026
TechStock²"Top-line results are expected in 1H 2026, with a Biologics License Application (BLA) filing planned in 2H 2026 and a potential first FDA approval by 2027."Sep 15, 2026
Merlintrader Trading Pub"Review, manufacturing, safety and labeling risks remain: acceptance is not approval, and the FDA can change its target date."Sep 30, 2026
Kalshi"Kalshi predicts a 93% probability that the FDA will approve lonvo-z before July 2027."Sep 30, 2026
FierceBiotech.comThe treatment is currently the subject of a rolling Biologics License Application (BLA) submission and is expected to launch in the first half of 2027.Oct 01, 2026
Zacks Investment Research"The FDA is expected to pass a final decision on the lonvo-z BLA by March 10, 2027."Sep 09, 2026
© 2026 Improve the News Foundation. All rights reserved.Version 7.18.0
© 2026 Improve the News Foundation.
All rights reserved.
Version 7.18.0